White Papers

1. Reducing Inventory Errors In Clinical Trials 5/8/2026

   Can a digital double-check save your trial from data errors? How does verifying shipments at receipt slash inventory mistakes? Learn to protect protocol integrity and patient safety.

2. Go From Three Meetings To One With AI-Enabled eCOA 5/5/2026

   Learn how to turn three meetings into one with AI that is streamlining clinical workflows by reducing redundant steps, simplifying site operations, and accelerating data collection.

3. US Healthcare System Overview 4/29/2026

   A clear guide to U.S. coverage, regulation, and reimbursement: who decides care, how products gain access, and how policy and financing shape cost, value, and patient access.

4. Why RWD Strategy Can't Wait With Price, Value And Evidence Pressures Everywhere 4/27/2026

   Overcome pricing pressures and reimbursement delays by integrating real-world evidence early in development to align clinical outcomes with payer demands and accelerate patient access.

5. Why Life Science Organizations Need A Chief Patient Officer Function 4/27/2026

   Bridging the gap between innovation and impact, this exploration of the Chief Patient Officer role offers a strategic framework to integrate patient insights and de-risk the product lifecycle.

6. The Next Era Of eCOA Is AI 4/15/2026

   Discover how AI is moving beyond the hype to streamline clinical study builds. Explore practical ways to automate protocol digitization and UAT scripts while preparing for future patient tools.

7. Futureproofing Post-Approval Compliance 4/15/2026

   In the post-approval stage, a synergistic operating model brings PV and regulatory functions under one umbrella: a single governance structure with shared decision cycles, templates, and evidence.

8. Pharma R&D Annual Review Supplement: New Active Substances 4/15/2026

   Last year was by some distance the best year ever in terms of new active substances. Its total of 105 new debuts easily outstrips that of the previous record holder 2021’s 97. In 2025 we saw 97 new drugs, compared to the previous record of 84.

9. What Re-Acquisition In Retinal Imaging Is Really Costing Your Program 4/6/2026

   High screen failure rates and patient dropout often stem from preventable imaging errors. Learn how proactive quality control and patient-centric logistics secure critical retinal trial data.

10. A New Era Of ADC Development Demands A New Kind Of Partner 3/30/2026

    Explore how to navigate the evolution of antibody-drug conjugates by mastering AI-driven selection, dose optimization, and new regulatory strategies for earlier-line clinical success.